Clinical Edge Journal Scan

Teriparatide can be considered in premenopausal women with idiopathic osteoporosis


 

Key clinical point : Teriparatide improves bone formation rate (BFR), bone turnover markers, and spine and hip bone density in premenopausal women with idiopathic osteoporosis (IOP).

Major finding : At 6 months, teriparatide significantly increased lumbar spine (LS) areal bone mineral density (aBMD) vs placebo (percentage change: 5.51% vs. 1.55%; P = .007). At 24 months, teriparatide significantly increased aBMD of LS, total hip, and femoral neck (percentage change: 13.2%, 5.2%, and 5.0%, respectively; P ≤. 001 for all). Cancellous and intracortical BFR increased 3.3-fold ( P ≤. 001) and 1.9-fold ( P ≤. 001), respectively, in the teriparatide group with no change in placebo group. Serum N-terminal propeptides of procollagen type 1, osteocalcin, and C-telopeptide increased significantly by 3 months with teriparatide treatment.

Study details : The data come from a phase 2 trial of 41 premenopausal women with IOP who were randomly assigned to either teriparatide 20 mcg (n = 28) or placebo (n = 13). After 6 months, placebo group was switched to teriparatide for 24 months, and the teriparatide group continued the drug for 18 months.

Disclosures: The study was supported by the United States Food and Drug Administration Orphan Products Clinical Trials Grants Program. A Cohen, E Shane, RR Recker, and JM Lappe received research support from Amgen and Eli Lilly. DW Dempster received research support and consulting fees from Amgen, Eli Lilly, and Radius Health.

Source: Cohen A et al. J Clin Endocrinol Metab. 2020 Sep 2. doi: 10.1210/clinem/dgaa489 .

Recommended Reading

Pro-inflammatory diets tied to osteoporosis risk
MDedge Rheumatology
Postmenopausal osteoporosis: Factors influencing early treatment with romosozumab
MDedge Rheumatology
Association between serum magnesium concentration and postmenopausal osteoporosis
MDedge Rheumatology
Delayed denosumab injections raise vertebral fracture risks in osteoporosis
MDedge Rheumatology
Initiation of antiosteoporotic drugs in women starting glucocorticoid treatment
MDedge Rheumatology
Osteoporosis: Cardiovascular safety of abaloparatide in postmenopausal women
MDedge Rheumatology
Psoriatic arthritis, psoriasis, and osteoporosis: What is the association?
MDedge Rheumatology
Glucocorticoid-induced osteoporosis: Teriparatide may be a good alternative to denosumab
MDedge Rheumatology
Osteoporosis: September 2020
MDedge Rheumatology
Denosumab safe and effective in chronic liver disease patients with osteoporosis
MDedge Rheumatology